This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Multiple sclerosisMultiple Sclerosis (MS)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G35 | Special Copayment Reduction: V022 | Coverage period: 5 years
B. SynonymsMultiple sclerosis, multiple sclerosis of brainstem, multiple sclerosis of cord, multiple sclerosis NOS, generalized multiple sclerosis, disseminated multiple sclerosis, Disseminated sclerosis, Encephalomyelitis disseminata
C. Adult onsetLikelihood of first onset in adulthood: very high — Typically onset in women in their 20s–40s (relapsing-remitting); PPMS has onset in the 40s–50s with little sex difference
1. History1. History
2. Causes2. Causes
3. Genetics3. Genetics
4. Epidemiology4. General epidemiology
5. Pathophysiology5. Pathophysiology
6. Symptoms6. Symptoms
7. Signs7. Signs
8. Screening8. Screening
9. Diagnosis9. Diagnosis
10. Treatment10. Treatment
11. Prognosis11. Prognosis
12. Prevention12. Prevention
13. References13. References

1. History

The first systematic description of multiple sclerosis (MS) was made in 1868 by the French neurologist Jean-Martin Charcot (1825–1893). In Leçons sur les maladies du système nerveux, Charcot described as "la sclérose en plaques" a clinical syndrome including three signs—spasticity, nystagmus, and intention tremor (later 'Charcot's triad')—and linked it with neuropathological findings. However, even earlier, in the early 19th century, there are records of the Scottish physician Robert Carswell (1793–1857) and the French Jean Cruveilhier (1791–1874) depicting plaque-like lesions in anatomical specimens.

In the early 20th century, the episodic course and relapsing-remitting pattern were recognized clinically, and in the 1950s oligoclonal bands (OCB) were discovered on cerebrospinal fluid protein electrophoresis, supporting the immunological basis of MS. The Poser diagnostic criteria were proposed in 1983, and the McDonald criteria of 2001, which incorporated MRI findings, became the international standard for clinical diagnosis. They have since been updated in stages in 2005, 2010, 2017, and up to the 2024 revision, which added new biomarkers such as the central vein sign and paramagnetic rim lesions. On the treatment side, since interferon beta-1b (Betaseron) received FDA approval in 1993 as the first disease-modifying therapy (DMT), more than 30 DMTs have been approved to date.

2. Causes

MS is a multifactorial autoimmune disease in which genetic predisposition and environmental factors act in combination; it is not a disease with a single cause.

Environmental risk factors

Immunological mechanisms

T cell (CD4⁺ Th1/Th17)- and B cell-mediated autoimmune responses against myelin of the CNS white matter are central. It has been proposed that cross-reactivity between the EBV antigen (EBNA1) and myelin basic protein (MBP) or the glycoprotein GlialCAM through molecular mimicry induces autoimmunity.

3. Genetics

The genetic risk of MS is about 25–30% in monozygotic twins and about 5% in dizygotic twins, and the risk in first-degree relatives compared with the general population is about 2–4%. MS is a complex genetic disease, not a single-gene disease.

HLA genes

HLA-DRB1*15:01 is the genetic risk factor most strongly associated with MS (OR ≈ 3.0). In populations of European descent, about 60% of MS patients carry this allele. HLA-A*02:01 is a protective allele that reduces MS risk by about 40%. Additional HLA risk variants such as HLA-DRB1*03:01 and HLA-B*44:02 have also been identified.

Non-HLA genes

Since 2011, large GWAS have confirmed that more than 230 non-HLA single nucleotide polymorphisms (SNPs) are associated with MS risk. Major genes include immune-related pathway genes such as IL2RA (CD25), IL7R, IRF8, STAT3, CLEC16A, CYP27B1 (vitamin D metabolism), and TNFRSF1A. The effect size (OR) of each variant is mostly small, at around 1.1–1.3, and combinations of many variants contribute to disease risk.

Genetic counseling

The risk in children of MS patients is about 2–3 times that of the general population (lifetime risk about 2–5%). Research on personalized risk prediction using HLA typing and polygenic risk scores (PRS) is under way, but there is currently no basis for routinely performing genetic testing in clinical genetic counseling.

4. General epidemiology

MS is estimated to affect more than about 2.8 million patients worldwide (2020 MSIF report). Prevalence shows a latitude gradient and is highest in Northern Europe and North America (over 200–300 per 100,000 population in some regions). Prevalence is low in equatorial regions.

The sex ratio is female : male ≈ 3:1 (for RRMS). In PPMS, the sex difference is small, close to about 1:1. The typical age of onset is 20–40 years for RRMS, while PPMS most commonly begins in the 40s–50s. Pediatric MS (under age 15) accounts for about 3–5% of the total.

Korea was formerly classified as a country with low MS prevalence, but prevalence has recently been reported at about 3.5–5 per 100,000, and the number of registered patients is steadily increasing with improved diagnostic techniques and greater awareness. Studies are accumulating on phenotypic overlap with neuromyelitis optica spectrum disorder (NMOSD) and the frequency of AQP4 antibody-negative MS in Korean MS patients.

Distribution by MS type: RRMS about 85%, SPMS (converted from RRMS) about 10–15% (at 20-year follow-up after diagnosis), PPMS about 10–15%.

5. Pathophysiology

The pathophysiology of MS is broadly divided into three stages: ① inflammatory demyelination, ② axonal damage and neurodegeneration, and ③ incomplete remyelination.

Autoimmune inflammatory response

Autoreactive CD4⁺ Th1 and Th17 cells activated in the periphery cross the blood-brain barrier (BBB) and infiltrate the CNS. BBB passage is mediated by matrix metalloproteinases (MMPs), integrins (especially α4β1, VLA-4), and the CXCL10/CXCR3 axis. Within the CNS, these T cells, after re-exposure to myelin antigens (MBP, PLP, MOG, etc.), secrete cytokines such as interferon-γ (IFN-γ, Th1), interleukin-17 (IL-17, Th17), and TNF-α, activating microglia and macrophages.

B cells and plasma cells produce antibodies against myelin antigens (e.g., anti-MOG IgG is present in some), accelerating myelin damage through complement activation. Oligoclonal bands (OCB) in the cerebrospinal fluid reflect local production of immunoglobulin within the CNS.

Axonal damage and neurodegeneration

In demyelinated axons, saltatory conduction becomes impossible due to loss of the nodes of Ranvier, and excessive Na⁺/Ca²⁺ influx due to ion channel redistribution (Nav1.2→Nav1.6) causes axonal degeneration. Mitochondrial dysfunction and oxidative stress accompany this, forming the basis of progressive disability. Elevated serum and cerebrospinal fluid levels of neurofilament light chain (NfL) are used as a biomarker of axonal damage.

Remyelination failure

In chronic lesions, oligodendrocyte precursor cells (OPCs) do not sufficiently mature and differentiate, so permanent myelin loss and neurodegeneration progress. Gliosis by activated microglia and astrocytes impedes remyelination.

6. Symptoms

MS symptoms vary with lesion location and either repeatedly relapse (relapse/exacerbation) and remit (remission) (RRMS) or progress gradually (PPMS, SPMS).

Initial symptoms (Clinically Isolated Syndrome, CIS)

Major symptom groups

7. Signs

The objective signs that can be identified on physical examination are as follows.

Ophthalmic and ocular signs

Motor and sensory signs

Cerebellar and brainstem signs

Cerebrospinal fluid and electrophysiological findings

8. Screening

There is no formal screening program for MS, but when clinically suspected, the following stepwise approach is recommended.

Clinical screening

In patients aged 20–50, when symptoms suggesting CNS demyelination, such as optic neuritis, sensory abnormalities, motor impairment, or diplopia, persist for 24 hours or more and are unrelated to fever or infection, evaluation for demyelinating diseases including MS is begun. If objective signs such as spasticity, INO, RAPD, or a Babinski sign are found on neurological examination, the patient is referred for further detailed testing.

MRI screening

Brain and spinal cord MRI (including gadolinium contrast) is the key screening tool. Typical MS lesions are T2/FLAIR hyperintense lesions located periventricularly, cortically/juxtacortically, in the cerebellar peduncles, and in the spinal cord. In the 2024 McDonald criteria, the central vein sign and paramagnetic rim lesions (PRL) were included as new biomarkers that increase specificity. PRLs are identified on 7T MRI as iron-laden microglial rims of chronic active lesions.

Serum biomarker screening

Serum neurofilament light chain (sNfL) levels are being studied as a supplementary biomarker of disease activity and relapse prediction, but they have not yet been established as a routine screening criterion. AQP4-IgG and MOG-IgG testing is performed to differentiate from NMOSD and MOGAD.

9. Diagnosis

The 2024 revised McDonald criteria are the current standard for clinical application. The core principle of diagnosis is confirmation of dissemination in time (DIT) and dissemination in space (DIS).

Key points of the 2024 McDonald criteria

ItemCriteria
Dissemination in space (DIS)T2 lesions in 2 or more of the following 5 regions: periventricular, cortical/juxtacortical, juxtacortical, cerebellar peduncle, spinal cord. Optic nerve lesions are also newly included.
Dissemination in time (DIT)New T2 or enhancing lesions on MRI at different time points, or simultaneous presence of enhancing + nonenhancing lesions on the same MRI.
New markersCentral vein sign (CVS): supports MS diagnosis if ≥40% of T2/FLAIR lesions contain a central vein. The presence of paramagnetic rim lesions (PRL) contributes strongly to MS diagnosis.
OCBPositive CSF OCB can substitute for DIT.

Differential diagnosis

NMOSD (AQP4-IgG, MOG-IgG testing), MOGAD, CNS vasculitis, Susac syndrome, neurosarcoidosis, neurolupus, CADASIL, cerebral small vessel disease, vitamin B12 deficiency (subacute combined degeneration), and others must be excluded.

10. Treatment

MS treatment consists of four pillars: ① treatment of acute relapses, ② disease-modifying therapy (DMT), ③ symptom management, and ④ rehabilitation.

Treatment of acute relapses

For relapses accompanied by clinically significant neurological worsening, high-dose methylprednisolone 1,000 mg/day is given intravenously for 3–5 days to shorten the relapse. Patients should be told that steroid treatment does not change long-term accumulation of disability. For steroid-refractory relapses, 5–7 sessions of plasma exchange (PLEX) can be performed.

Disease-Modifying Therapy (DMT)

DMTs aim to reduce relapse frequency, suppress new MRI lesions, and delay disability progression, and are classified by efficacy into first-line (moderate efficacy) and high-efficacy agents. Recent guidelines, as evidence accumulates on the long-term benefits of early high-efficacy therapy (EHT), emphasize individualized treatment strategies according to patient characteristics, risk factors, and preferences.

Interferon beta (IFN-β)

There are IFN-β-1a (Avonex 30 μg IM once weekly; Rebif 22/44 μg SC three times weekly) and IFN-β-1b (Betaseron/Betaferon 250 μg SC every other day). They reduce the relapse rate by about 30% and have proven efficacy in suppressing MRI lesions. Main adverse effects are injection site reactions, flu-like symptoms, liver function test abnormalities, and formation of neutralizing antibodies. Neutralizing antibodies occur more commonly with IFN-β-1b and can weaken treatment efficacy. Pegylated IFN-β-1a (Plegridy 125 μg SC every 2 weeks) has improved dosing convenience.

Glatiramer acetate (GA)

A mixture of synthetic peptides resembling MBP that suppresses CNS inflammation by inducing a Th2/regulatory T cell shift. Given as 20 mg SC daily or 40 mg SC three times weekly. Reduces the relapse rate by about 30%, similar to IFN-β. Main adverse effects: immediate post-injection reaction (flushing, chest tightness; mostly self-limiting), lipoatrophy. One of the relatively safe agents during pregnancy.

Natalizumab

A humanized monoclonal antibody that binds VLA-4 (α4β1 integrin), blocking passage of activated lymphocytes across the BBB. Given as 300 mg IV every 4 weeks. Compared with placebo, reduces the relapse rate by 68% and new T2 lesions by 83%. Main concern: progressive multifocal leukoencephalopathy (PML) caused by John Cunningham virus (JC virus). Anti-JC antibody positivity, prior immunosuppressant use, and treatment beyond 24 months are high-risk factors for PML. Regular monitoring of the anti-JC antibody index is mandatory.

Ocrelizumab

A humanized monoclonal antibody targeting CD20⁺ B cells. 600 mg IV every 6 months (initial 300 mg ×2, 2 weeks apart). In RRMS, reduces the relapse rate by 47% compared with placebo (OPERA trials); in PPMS, reduces the risk of 12-week disability progression by 24% (ORATORIO trial)—the first DMT proven to suppress disability progression in PPMS. Main adverse effects: infusion-related reactions, increased infection risk due to B cell depletion (especially respiratory infections), decreased immunoglobulins, hepatitis B reactivation. HBV screening and confirmation that vaccinations are complete are mandatory before prescribing.

Siponimod and ofatumumab

Siponimod: An S1P receptor 1 and 5 modulator that sequesters lymphocytes in lymph nodes, inhibiting CNS infiltration. 1–2 mg orally once daily. Reduces the risk of 12-week disability progression by 21% in active SPMS (EXPAND trial). Dose adjustment according to CYP2C9 genotype is mandatory (*3 homozygotes: contraindicated). Monitor for QTc prolongation, bradycardia, macular edema, and elevated liver enzymes. Ophthalmologic examination is required before treatment.

Ofatumumab: A fully human anti-CD20 monoclonal antibody. 20 mg SC every 4 weeks (initial 20 mg ×3, 1 week apart). In RRMS, 50% superiority in relapse rate over teriflunomide (ASCLEPIOS trials). Self-injection offers high dosing convenience.

Other DMTs (key summary)

Treatment of PPMS

Ocrelizumab is the only FDA/EMA-approved DMT for PPMS. Since 2023, BTK inhibitors (evobrutinib, tolebrutinib, etc.) have been studied in phase 3 clinical trials in PPMS, and some results are being published.

Symptom management

11. Prognosis

The prognosis of MS varies greatly with type, early clinical course, treatment response, and patient characteristics. In RRMS, it has been reported that without treatment about 50% may convert to SPMS within 10 years and about 80–90% within 25 years, but since the introduction of high-efficacy DMTs, the rate of conversion to SPMS has decreased markedly. In PPMS, irreversible disability accumulates from the first visit, and the prognosis is poorer.

Poor prognostic factors: incomplete recovery after the first relapse, short interval between relapses, early accumulation of disability (EDSS 3 or higher), many enhancing lesions on brain MRI, accompanying spinal cord lesions, male sex, older age at onset, smoking. Favorable prognostic factors: optic neuritis alone as the first symptom, complete recovery, female sex, younger age at onset, low initial MRI lesion burden.

Observational evidence is accumulating that early administration of high-efficacy DMTs (natalizumab, ocrelizumab, etc.) increases the rate of achieving NEDA-3 (no evidence of disease activity: no relapses, no MRI lesion progression, no disability progression) and improves long-term prognosis. A decrease in serum NfL levels is used as an objective biomarker of treatment response.

12. Prevention

Primary prevention of MS is currently not possible, but risk factor management and secondary prevention (preventing relapses and disability progression) are central to treatment.

Management of known risk factors (primary prevention at the research stage)

Secondary prevention

Promptly starting an appropriate DMT after early diagnosis is the most important secondary prevention strategy. Evidence has been established that, when CIS (clinically isolated syndrome) meets MRI criteria for MS, early initiation of DMT delays relapse and conversion to a formal MS diagnosis (CHAMPS, BENEFIT, REFLEX trials). Rehabilitation (physical therapy, occupational therapy, cognitive rehabilitation), exercise therapy (aerobic and resistance exercise), and psychological support contribute to maintaining function and improving quality of life.

13. References